A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea

Diabetes, Obesity and Metabolism

Volumn 16, Issue 5, 2014, Pages 443-450

  Moses, Robert G ^a   Kalra, S ^b   Brook, D ^c   Sockler, J ^d   Monyak, J ^c   Visvanathan, J ^c   Montanaro, M ^c   Fisher, S A ^c  

^a Wollongong Diabetes Service   (Australia)

^b Bharti Research Institute of Diabetes and Endocrinology ^*  (India)

^c ASTRAZENECA   (United Kingdom)

^d Datapharm Australia Pty Ltd   (Australia)

Author keywords

Antidiabetic drug; Clinical trial; DPP 4 inhibitor; Glycaemic control; Incretin therapy; Type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; METFORMIN; PLACEBO; SAXAGLIPTIN; SULFONYLUREA; ADAMANTANE; ANTIDIABETIC AGENT; DIPEPTIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; SULFONYLUREA DERIVATIVE;

ADD ON THERAPY; ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CONFIDENCE INTERVAL; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; TREATMENT OUTCOME; URINARY TRACT INFECTION; ANALOGS AND DERIVATIVES; AUSTRALIA; BLOOD; CANADA; CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; INDIA; KOREA; METABOLISM; PHASE 3 CLINICAL TRIAL; THAILAND; UNITED KINGDOM;

ADAMANTANE; ADULT; AUSTRALIA; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHT; CANADA; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GREAT BRITAIN; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INDIA; KOREA; MALE; METFORMIN; MIDDLE AGED; SULFONYLUREA COMPOUNDS; THAILAND; TREATMENT OUTCOME;

EID: 84898789442     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12234     Document Type: Article

References (23)

1. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
2. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
3. UK Prospective Diabetes Study Group. U.K. prospective diabetes study 16. Overview of 6years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249-1258.
4. Turner RC, Cull CA, Frighi V, Holman RR, for the UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005-2012.
5. Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 2004; 27: 1535-1540.
6. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-1705.
7. ® (saxagliptin). Full Prescribing Information, Bristol-Myers Squibb/AstraZeneca Pharmaceuticals LP, Princeton, NJ/Wilmington, DE, 2011.
8. Rosenstock J, Aguilar-Salinas C, Klein E, Nepal S, List J, Chen R, for the CV181-011 Study Investigators. Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin 2009; 25: 2401-2411.
9. DeFronzo RA, Hissa MN, Garber AJ et al., for the Saxagliptin 014 Study Group. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009; 32: 1649-1655.
10. Fonseca V, Zhu T, Karyekar C, Hirshberg B. Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage. Diabetes Obes Metab 2012; 14: 365-371.
11. Göke B, Gallwitz B, Eriksson J, Hellqvist A, Gause-Nilsson I. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. Int J Clin Pract 2010; 64: 1619-1631.
12. Jadzinsky M, Pfvtzner A, Paz-Pacheco E, Xu Z, Allen E, Chen R, and the CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009; 11: 611-622.
13. Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R, for the CV181-040 Investigators. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract 2009; 63: 1395-1406.
14. Hollander P, Li J, Allen E, Chen R, for the CV181-013 Investigators. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab 2009; 94: 4810-4819.
15. Barnett AH, Charbonnel B, Donovan M, Fleming D. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Curr Med Res Opin 2012; 28: 513-523.
16. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
17. Vilar L, Gusmao A, Albuquerque JL et al. Effectiveness of adding vildagliptin to the treatment of diabetic patients nonresponsive to the combination of metformin and a sulphonylurea. Arq Bras Endocrinol Metabol 2011; 55: 260-265.
18. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P, and Sitagliptin Study 035 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007; 9: 733-745.
19. ® (sitagliptin). Full Prescribing Information, Whitehouse Station, NJ, Merck & Co., Inc., 2012.
20. Tradjenta™ (linagliptin). Full Prescribing Information, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, 2012.
21. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med 2012; 29: 682-689.
22. International Diabetes Federation. Global guideline for type 2 diabetes. International Diabetes Federation, 2012. Available from URL: http://www.idf.org/sites/default/files/IDF-Guideline-for-Type-2-Diabetes.pdf. Accessed 12 July 2013.
23. Scirica BM, Bhatt DL, Braunwald E et al. The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study. Am Heart J 2011; 162: 818-825.